Purpose ROS1 gene fusions demonstrate oncogenic activity, and patients with non-small-cell lung cancer (NSCLC) harboring a ROS1 fusion benefit from the use of a ROS1 inhibitor; however, clinical response to ROS1 inhibitors remains largely uncharacterized outside of NSCLC. ROS1 fusions have been identified in multiple tumor types but have not been reported in cutaneous melanoma.
INTRODUCTION
ROS1 is a receptor tyrosine kinase (encoded by the ROS1 gene) in the insulin receptor family that is involved in oncogenic chromosomal translocations. 1 Gene fusions including the receptor tyrosine kinase-encoding ROS1 gene were first identified in a human glioblastoma cell line and have subsequently been identified in multiple cancers, including non-small-cell lung cancer (NSCLC), ovarian cancer, cholangiocarcinoma, and others. [2] [3] [4] [5] [6] Patients with NSCLC with ROS1 fusion-positive cancers respond to treatment with crizotinib, a smallmolecule tyrosine kinase inhibitor, and this drug is now US Food and Drug Administration approved in the United States for this subset of patients. 7 However, the response to ROS1 inhibitors has not been thoroughly characterized in tumor types outside of NSCLC, and it remains an open question whether the cellular context of different tumor types and cell origins may affect response to ROS1 inhibiton.
Fusions in ROS1, NTRK1, NTRK2, NTRK3, and ALK genes have been reported in Spitz neoplasms and Spitzoid melanoma; however, they have not been identified in cutaneous malignant melanomas. [8] [9] [10] Acral lentiginous melanoma (ALM) is a less common subtype of melanoma that arises on non-hair-bearing skin (glabrous skin) such as the palms of the hand, the soles of the feet, and underneath fingernails and toenails. ALM is not related to sun exposure and has a lower mutational burden but higher degree of chromosomal instability compared with sunexposed melanoma. [11] [12] [13] One study identified ALK fusions in ALM tumors; however, fusions in genes other than ALK have not been studied in ALM. 
PATIENTS AND METHODS

Patient Samples
Targeted RNA Sequencing
Gene rearrangements and fusions were analyzed by targeted RNA sequencing, using an anchored multiplex polymerase chain reaction (PCR) method (ArcherDx, Boulder, CO) as previously described.
15
Reverse-Transcriptase PCR and Sanger Sequencing
Total RNA was isolated from frozen tumor using the RNeasy Plus Mini Kit (Qiagen, Hilden, Germany). cDNA was synthesized using the Verso cDNA kit (Thermo Fisher Scientific, Waltham, MA), followed by PCR amplification using GoTaq (Promega, Madison, WI) and GOPC-ROS1-specific primers (sense, 59-AGAGCTT-GAGGCAAACAA-39; antisense, 59-CCACTG-CTGTTCCTTCATACA-39). Purified PCR products were sequenced using the BigDye Terminator Cycle Sequencing Ready Reaction kit (version 3.1; Applied Biosystems, Foster City, CA). No. 1108743-60-7) in 200-mg tablets provided by the study sponsor. Efficacy during this study was evaluated using RECIST (version 1.1) criteria. Patients received continuous dosing once daily until intolerable toxicity, disease progression, or withdrawal of consent.
Clinical Trial
Immunohistochemistry
Tissue microarrays (made from 1.5-mm punches of formalin-fixed paraffin-embedded blocks of tumor from patients with melanoma) and individual patient tumor slides were analyzed by ROS1 immunohistochemistry (IHC) staining as previously described. 16 
RESULTS
Identification of ROS1 Fusion in Patient With ALM
We analyzed tumors from 22 patients with ALM using targeted RNA sequencing to determine the presence or absence of fusions in the ROS1, NTRK1, NTRK2, NTRK3, and ALK genes. A fusion containing exons 1 to 4 of the GOPC gene and exons 36 to 42 of the ROS1 gene was detected in one patient (Table 1 ; Fig 1A) . Expression of the GOPC-ROS1 fusion transcript was confirmed using reverse-transcriptase PCR followed by Sanger sequencing (Fig 1B) , and IHC of the tumor sample confirmed ROS1 protein expression ( Fig 1C) .
The patient with the GOPC-ROS1 fusion is a 46-year-old man who was initially diagnosed with ALM in 2010. He presented for evaluation of a persistent ulcerating 4-mm lesion on the tip of his fifth left toe. Biopsy revealed ALM. The patient then underwent amputation of the fifth toe with left groin sentinel lymph node biopsy followed by amputation of the fourth left toe and resection of a satellite nodule. Because of high-risk disease, the patient underwent complete left inguinal lymph node dissection and received adjuvant biochemotherapy with cisplatin, vinblastine, dacarbazine, aldesleukin, and interferon alfa-2b.
Approximately 1 year later, a recurrence was detected in the surgical scar, and this was reresected, followed later by recurrent in-transit metastases. Mutation testing showed the tumor was wild type for BRAF and KIT genes. The patient then received multiple therapies, none of which led to an objective tumor response, including ipilimumab (anti-CTLA4), paclitaxel per randomized trial, pembrolizumab (programmed death-1 inhibitor), interleukin-2, stereotactic body radiotherapy, surgical excision, nivolumab (programmed death-1 inhibitor), dacarbazine, cisplatin, and carmustine.
Patient With ROS1 Fusion Responds to Treatment With Entrectinib
Given the ROS1 fusion and the potential for response to targeted treatment, treatment options included off-label crizotinib, which is effective in ROS1-positive NSCLC tumors, or a phase I clinical trial of the CNS-penetrant ROS1/TRK/ALK inhibitor entrectinib. The patient was found eligible for this trial and provided written informed consent. At baseline, the patient had several palpable masses in the left leg, ranging from approximately 1 to 4 cm (Figs 2A to 2C) , as well as a 12-mm nodal mass in the paratracheal lymph node and a small right subpleural pulmonary nodule (data not shown).
The patient initiated entrectinib 600 mg orally once per day, and after 2 weeks, four of the five main lesions on the left leg were no longer palpable. A restaging computed tomography scan at 3 months showed significant regression in multiple lesions (Fig 2; data not shown). This corresponds with a 238% tumor shrinkage, a partial response as determined by RECIST (version 1.1) in his target lesions. At 11 months, target lesions showed a total decrease to 255% by RECIST (version 1.1). Overall, the patient is experiencing an ongoing partial response to therapy by RECIST (version 1.1) and has no evidence of disease progression at 11 months. The patient developed grade 1 dyspnea and weight gain, but overall, entrectinib has been well tolerated.
ROS1 Fusions Resulting in Expression Are Infrequent in Cutaneous Malignant Melanomas
Endogenous ROS1 is not expressed in melanoma; however, ROS1 fusions resulting in expression have been reported to occur at a frequency of approximately 17% in Spitz neoplasms, which is significantly higher than the reported frequency in other cancer types, such as NSCLC, where it is only observed in 1% to 2%. 8, 17 To estimate the frequency of expressed ROS1 fusions across different subtypes of malignant melanoma, we performed ROS1 IHC on tissue microarrays and individual tumor slides representing 78 patients with superficial spreading, nodular, or mucosal melanoma or ALM. Staining was scored on a scale from 0 to 2+, and all samples scored a 0, except for two samples from one patient, which were scored 1+ and corresponded to the study patient described here (Table 2 ). Altogether, we screened a total of 33 tumors from patients with ALM by IHC and/or targeted sequencing and only found the one GOPC-ROS1 fusion, resulting in a ROS1 frequency of 3.0% in ALM. 
DISCUSSION
Although ROS1 fusions have been identified in other subtypes of melanoma, they have not been previously identified in ALM or other cutaneous melanomas. Additionally, there is little information on the effectiveness of targeted therapies in patients who harbor ROS1 gene fusions outside of NSCLC. In our series, we found one (3.0%) of 33 ALMs demonstrated ROS1 expression and harbored the GOPC-ROS1 fusion. This frequency is similar to that observed for other cancer types where ROS1 fusions have been detected, such as NSCLC, but lower than frequencies reported for Spitzoid neoplasms and Spitzoid melanomas. 8, 17 We did not find any ROS1 expression-positive cases in 30 superficial spreading or nodular melanoma cases, consistent with the previous study conducted on 374 cutaneous melanomas. 10 We also did not find any ROS1 expression-positive cases in the 18 mucosal melanomas; however, the number of patients needed to estimate the true frequency likely needs to be much larger. Although we found the overall ROS1 fusion frequency to be 1.3% across all melanoma subtypes, the dramatic treatment response described in this report should prompt additional screening and studies of ROS1 fusions in patients with melanoma.
Although entrectinib has shown activity against ROS1 fusion tumors in NSCLC, 18 this is the first report to our knowledge of entrectinib response against a ROS1 fusion outside of lung cancer. Entrectinib has previously demonstrated antitumor response in patients with tumors that are positive for ALK or NTRK1-3 gene fusions in indications outside of NSCLC, such as colorectal cancer, 19, 20 astrocytoma, 18 and mammary analog secretory carcinoma. 21 Altogether, the tumor response observed in this patient with ROS1-positive melanoma is adding toagrowingbodyofliterature suggestinggene fusions in ROS1, NTRK1-3, and ALK may be generally responsive to their respective tyrosine kinase inhibitors, irrespective of the tumor histology context. 
